Publications

Researched and Curated by Clinical and Scientific Experts.

Every Hayes clinical evidence report is developed by experienced teams that have been trusted by healthcare decision makers since 1989. Here is a sampling of our content that is being used every day to inform defensible, evidence-based decisions by payers and providers.

Not all reports are available for public preview. For more information, please contact us.

Humacyl Acellular Vessel

Humacyl is an off-the-shelf bioengineered human acellular vessel proposed for use as a hemodialysis access graft in patients with end stage renal disease (ESRD). This technology uses a process to decellularize donated human vascular smooth muscle cells, while preserving extracellular matrix proteins. This results in a tubular scaffold that is acellular at the time of implanta…

read more

Noninvasive Computed Fractional Flow Reserve from Computed Tomography (FFRCT) for Diagnosis of Coronary Artery Disease

Focus of the Report: This report focuses on fractional flow reserve (FFR), determined noninvasively via computed tomography (FFRCT), to detect coronary artery blockages, identified by coronary computed tomography angiography (CCTA), that may be responsible for myocardial ischemia in patients with known or suspected coronary artery disease (CA…

read more

Anifrolumab for Systemic Lupus Erythematosus

Anifrolumab is an investigational fully human monoclonal antibody that binds to subunit 1 of the type I interferon (IFN) receptor, blocking the activity of all type I IFNs. It is proposed for the treatment of adults with moderately to severely active systemic lupus erythematosus (SLE) who are receiving standard care.

read more